BIO-Europe Spring® 2017: Seventure Partners predicts bright future for microbiome opportunities

April 7, 2017

Seventure Partners’ Eric de la Fortelle explains to Informa Pharma Intelligence’s Mike Ward how the venture capitalist’s EUR 160 million fund will prosper from the increased understanding of human and microbe interactions. Seventure has just published a report on the emergence of the microbiome as an intense area of interest in the biotech industry, starting with the advent of deep sequencing technology in the early 2000s and moving toward the Phase II trials in progress now.

Click here for more coverage of the activities held during BIO-Europe Spring

Previous Video
BIO-Europe Spring® 2017: Ergomed's evolution and risk-sharing business model in practice
BIO-Europe Spring® 2017: Ergomed's evolution and risk-sharing business model in practice

Over the last decade Ergomed has evolved from a contract research organization into a clinical-stage drug d...

Next Video
BIO-Europe Spring® 2017: Atriva repurposes cancer drug candidates to create universal flu treatment
BIO-Europe Spring® 2017: Atriva repurposes cancer drug candidates to create universal flu treatment

Dr. Rainer Lichtenberger, CEO of Atriva Therapeutics, a 2015 startup, explains to Mike Ward, head of pharma...